{
  "id": "PK_CYP3A4_STRONG_INHIB",
  "name": "Strong CYP3A4 inhibition increases exposure of CYP3A4 substrates",
  "domain": "PK",
  "severity": "major",
  "rule_class": "adjust_monitor",
  "actions": [
    "Consider alternative to the CYP3A4 inhibitor when feasible (educational).",
    "If used together, monitor for dose-related adverse effects of the affected drug.",
    "Be cautious with sedating or hypotensive substrates."
  ],
  "logic": {
    "enzyme": {
      "id": "CYP3A4",
      "A_role": "substrate",
      "B_role": "inhibitor",
      "B_strength": "strong"
    },
    "rationale": [
      "B inhibits CYP3A4, a major metabolic pathway for A.",
      "Reduced metabolism can increase A systemic exposure and peak concentrations."
    ]
  },
  "explanation_template": "{B_name} is a strong CYP3A4 inhibitor and {A_name} is a CYP3A4 substrate. This can increase {A_name} exposure, raising the risk of dose-related adverse effects.",
  "references": [
    {
      "source": "Educational note",
      "citation": "Mechanistic pattern: strong enzyme inhibition + substrate increases exposure."
    }
  ]
}
